[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"premature-coronary-heart-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:premature-coronary-heart-disease":111},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,61,92],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053702",false,"NCT06164730","A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease","Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol","Inclusion Criteria:\n\n* Diagnosis of HeFH or premature CAD\n\nExclusion Criteria:\n\n* Homozygous familial hypercholesterolemia\n* Active or history of chronic liver disease\n* Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe\n* Clinically significant or abnormal laboratory values as defined by the protocol","ALL","18 Years","70 Years",{"count":19,"type":20},85,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.",[26,27],"Heterozygous Familial Hypercholesterolemia","Premature Coronary Heart Disease",[29,30,31,32,33,34,35],"VERVE-102","Familial Hypercholesterolemia","Coronary Artery Disease","Dose Escalation","Gene Editing","Base Editing","heart-2","RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":40},"2024-04-30",{"date":44,"type":20},"2027-08",{"name":46,"class":47},"Verve Therapeutics, Inc.","INDUSTRY",24,{"id":50,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":24,"conditions":53,"keywords":54,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":60,"locationsCount":48},"100528742",{"count":19,"type":20},[23],[26,27],[29,30,31,32,33,34,35],"2026-06-26",{"date":57,"type":40},"2026-06-29",{"date":42,"type":40},{"date":44,"type":20},{"name":46,"class":47},{"id":62,"slug":4,"hasResults":10,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":71,"briefSummary":73,"conditions":74,"keywords":75,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":91},"100595367","NCT07031531","Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease","Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease (SMART-CHD): A Prospective, Multicenter, Open-Label, Randomized Controlled Trial","SMART-CHD","Inclusion Criteria\n\n1. Patients with coronary heart disease aged 18-45 years;\n2. The patient or a close family member is capable of using a smartphone and mobile application (App);\n3. Willing to participate in the study and able to provide written informed consent.\n\nExclusion Criteria\n\n1. Severe cognitive impairment;\n2. Advanced-stage malignancy;\n3. Life expectancy less than 12 months;\n4. Severe multi-organ failure;\n5. Refusal to provide written informed consent.","45 Years",{"count":70,"type":20},4900,[72],"NA","The goal of this clinical trial is to learn if an AI-enabled stratified management system (SMART-CHD) can improve post-discharge outcomes in adults aged 18-45 with premature coronary artery disease. The main questions it aims to answer are:\n\n1. Does SMART-CHD reduce the combined rate of all-cause death, myocardial infarction, stroke and rehospitalization within 12 months?\n2. Does SMART-CHD achieve better control of modifiable risk factors compared with usual care?\n\nResearchers will compare SMART-CHD to standard discharge management (verbal and printed instructions on medications, follow-up timelines and lifestyle advice) to see if the AI-driven platform leads to fewer adverse events and improved risk-factor profiles.\n\nParticipants will:\n\n1. Install and use the SMART-CHD mobile app after a 10-minute structured orientation session with supervised simulations.\n2. Complete regular in-app surveys on lifestyle behaviors, laboratory\u002Fimaging results and clinical events (with OCR-powered LLM assistance).\n3. Wear paired sensors for continuous monitoring of blood pressure, heart rate and other physiologic metrics.\n4. Receive automated EHR data harvesting, AI-driven voice-call reminders, and real-time CRC support via a dedicated WeChat group.\n5. Follow personalized, guideline-based risk-factor recommendations (diet, exercise, sleep, weight, smoking, alcohol, hypertension, dyslipidemia, diabetes).",[27],[76,77,78,79,80],"Premature coronary heart disease","secondary prevention","long-term management","mobile health","artificial intelligence","2025-09-18",{"date":83,"type":40},"2025-09-23",{"date":85,"type":40},"2025-08-08",{"date":87,"type":20},"2027-07-31",{"name":89,"class":90},"China National Center for Cardiovascular Diseases","OTHER_GOV",16,{"id":93,"slug":4,"hasResults":10,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":68,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100593285","NCT07004452","Multi-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial","Inclusion Criteria:\n\n* Age 18-45 years;\n* Clinically confirmed CAD with ≥50% luminal stenosis in at least one major coronary artery or significant branch, verified by coronary angiography;\n* For acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) patients: clinical stability meeting discharge criteria post-treatment;\n* Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n* Heart transplant recipients;\n* Severe systemic comorbidities with life expectancy \\\u003C1 year;\n* Previous enrollment in other drug\u002Fdevice clinical trials without completing the primary endpoint observation period;\n* Inability to comply with follow-up (e.g., dementia, severe psychiatric disorders).",{"count":98,"type":20},5000,"OBSERVATIONAL","The goal of this observational cohort study is to establish a risk prediction model for adverse events in Chinese individuals under 45 years old with premature coronary artery disease. The main questions it aims to answer are:\n\n* What are the major risk factors for poor prognosis in Chinese patients with premature coronary artery disease?\n* What is the difference in the prognosis of patients with premature coronary heart disease with different phenotypes? Participants taking no mandatory intervention will be followed up for 2 year, with blood tests at 1 year and outpatient or telephone interviews at other timepoints.",[27],"2025-05-27",{"date":104,"type":40},"2025-06-04",{"date":106,"type":40},"2025-03-31",{"date":108,"type":20},"2027-07",{"name":89,"class":90},1,""]